Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
作者信息
Masters P, Shetty A
出版信息
BMJ. 1996 Nov 2;313(7065):1143; author reply 1144. doi: 10.1136/bmj.313.7065.1143a.
Abstract
摘要
相似文献
1
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.降低胆固醇的成本效益。他汀类药物治疗应尽早开始。
BMJ. 1996 Nov 2;313(7065):1143; author reply 1144. doi: 10.1136/bmj.313.7065.1143a.
2
Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.哪种他汀类药物治疗高胆固醇血症最有效？一项成本效益分析。
Clin Ther. 1999 Nov;21(11):1924-36. doi: 10.1016/S0149-2918(00)86740-5.
3
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.西班牙降胆固醇疗法的成本效益分析。
Am J Cardiovasc Drugs. 2006;6(3):177-88. doi: 10.2165/00129784-200606030-00005.
4
Cost of lipid-lowering statin drugs.降脂他汀类药物的成本。
Am J Cardiol. 1996 Jan 15;77(2):225-6. doi: 10.1016/s0002-9149(96)90609-8.
5
Fluvastatin cost considerations.氟伐他汀的成本考量。
Ann Pharmacother. 1994 Sep;28(9):1111-2. doi: 10.1177/106002809402800923.
6
[Which statin is more efficient? Concepts and applications in economic evaluation].[哪种他汀类药物更有效？经济评估中的概念与应用]
Aten Primaria. 2000 Sep 30;26(5):333-8. doi: 10.1016/s0212-6567(00)78676-8.
7
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.高胆固醇血症患者达到国家胆固醇教育计划（NCEP）目标的成本。阿托伐他汀、辛伐他汀、洛伐他汀和氟伐他汀的比较。
Pharmacoeconomics. 1998 Jul;14(1):59-70. doi: 10.2165/00019053-199814010-00006.
8
Maximizing the cost-effectiveness of lipid-lowering therapy.最大化降脂治疗的成本效益。
Arch Intern Med. 1998 Oct 12;158(18):1977-89. doi: 10.1001/archinte.158.18.1977.
9
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.一种评估他汀类药物在实现英国国家服务框架目标胆固醇水平方面成本效益的模型。
Pharmacoeconomics. 2003;21 Suppl 1:1-11. doi: 10.2165/00019053-200321001-00001.
10
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).阿托伐他汀比较胆固醇疗效与安全性研究（ACCESS）的经济分析。
Pharmacoeconomics. 2003;21 Suppl 1:13-23. doi: 10.2165/00019053-200321001-00002.
引用本文的文献
1
[Are the Framingham tables directly applicable to the Mediterranean population?].[弗雷明汉表格是否直接适用于地中海人群？]
Aten Primaria. 2002 Jun 15;30(1):29-31. doi: 10.1016/s0212-6567(02)78960-9.
本文引用的文献
1
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.他汀类药物降低已有或无冠心病患者胆固醇浓度的成本效益：应用于卫生当局人群的生命表法
BMJ. 1996 Jun 8;312(7044):1443-8. doi: 10.1136/bmj.312.7044.1443.
2
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.普伐他汀预防高胆固醇血症男性冠心病。苏格兰西部冠心病预防研究组。
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.
3
Should there be a moratorium on the use of cholesterol lowering drugs?是否应该暂停使用降胆固醇药物？
BMJ. 1992 Feb 15;304(6824):431-4. doi: 10.1136/bmj.304.6824.431.
Zotero 插件